Biopharmaceuticals company Zelira (ASX: ZLD) is taking a stab at redemption. After a misstep this July by not announcing its German expansion, the Company lost shareholder trust. Now, it is attempting to get it back with new milestones revealed on time for its clinical trials targeting diabetic nerve pain. The trial has been designed as
Read MoreFurthering their expertise in the field of cannabinoid-based therapeutics, Zelira Therapeutics (ASX: ZLD) is set to tap into the oral care market with the launch of hemp derived toothpaste in the United States. The toothpaste formulation was created by Sprinjene CEO and Founder, Dr Sayed Abrahim who developed the oral care product which is gluten-free,
Read MoreAustralian bio-pharmaceutical developer Zelda Therapeutics (ASX: ZLD) has now fully enrolled insomnia sufferers into clinical trials where the Company aims to use cannabis as a treatment for clinically diagnosed patients. This set of trials will be completed in collaboration with the University of Western Australia (UWA) Centre for Sleep Science. The trials will aim to
Read MoreThe content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.